HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Senate Wants PFAS Banned From Cosmetics. Should FDA Have A Say?

Executive Summary

Per- and polyfluoroalkyl substances are unpopular, sure. But there are thousands of PFAS with dissimilar safety profiles that merit US FDA review ahead of a blanket ban in cosmetic products, industry says.

You may also be interested in...



L’Oreal USA Dismisses Suit Alleging Deceptive Marketing Of PFAS-Containing Mascaras

The US District Court for the Southern District of New York grants L’Oréal USA’s motion to dismiss a putative class action in which plaintiffs say they would not have purchased or paid a premium price for the firm’s waterproof mascaras had they known of the presence of PFAS. According to the judge, the amended complaint lacks crucial evidence even at the pleading stage.

PFAS Disclosure, Supplier Contracts Can Help Shield Against Litigation – Dentons US Attorneys

Cosmetics companies that disclose the presence of PFAS in their products and explain measures they are taking to minimize PFAS’ presence are better protected from lawsuits, says Dentons US attorney Michael Duvall.

PFAS Remain High Priority For US FDA’s Cosmetics Office – Director Linda Katz

“We’ve been keeping tabs of the amount of products containing PFAS over the last several years and, unfortunately, we’re not seeing really a lot of it going away,” said Katz, director of the Office of Cosmetics and Colors, at the Independent Beauty Association’s Cosmetics Regulations Workshop.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151451

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel